Petra Muus


Ontology type: schema:Person     


Person Info

NAME

Petra

SURNAME

Muus

Publications in SciGraph latest 50 shown

  • 2021-03-04 Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia in LEUKEMIA
  • 2018-06-20 Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials in ANNALS OF HEMATOLOGY
  • 2017-06-26 Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2017-04-21 Clonal evolution in myelodysplastic syndromes in NATURE COMMUNICATIONS
  • 2015-11-23 Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group in ANNALS OF HEMATOLOGY
  • 2015-09-26 Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) in ANNALS OF HEMATOLOGY
  • 2015-09-24 Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG) in ANNALS OF HEMATOLOGY
  • 2014-11-17 High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT in BONE MARROW TRANSPLANTATION
  • 2014-08-07 Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies in ANNALS OF HEMATOLOGY
  • 2014-03-29 Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial) in ANNALS OF HEMATOLOGY
  • 2014-03-29 Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial in ANNALS OF HEMATOLOGY
  • 2013-04-09 Bone marrow histology in patients with a paroxysmal nocturnal hemoglobinuria clone correlated with clinical parameters in JOURNAL OF HEMATOPATHOLOGY
  • 2012-03-31 Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups in ANNALS OF HEMATOLOGY
  • 2012-02-23 Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON in LEUKEMIA
  • 2011-06-08 Need for early recognition and therapeutic guidelines of congenital sideroblastic anaemia in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2011-06-07 Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40 in LEUKEMIA
  • 2008-02-12 Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes in ANNALS OF HEMATOLOGY
  • 2006-08-17 Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial in LEUKEMIA
  • 2005-08-04 Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups in LEUKEMIA
  • 2003-05-01 The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921) in LEUKEMIA
  • 2002-08-30 Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors in LEUKEMIA
  • 2001-01-01 Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance in LEUKEMIA
  • 2001 Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes in ACUTE LEUKEMIAS VIII
  • 2000-08-01 Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia in LEUKEMIA
  • 1999 New Developments in the Treatment of Acute Myeloid Leukemia in DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III
  • 1998-06-29 Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission in BONE MARROW TRANSPLANTATION
  • 1997-08-01 Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial in BONE MARROW TRANSPLANTATION
  • 1997-04-01 Mosaicism of the 5q deletion as assessed by interphase FISH is a common phenomenon in MDS and restricted to myeloid cells in LEUKEMIA
  • 1997 Postremission Therapy: The Role of Allogeneic Bone Marrow Transplantation in Acute Myelogenous Leukemia: An Analysis of the AML8A EORTC-GIMEMA Protocol in ACUTE LEUKEMIAS VI
  • 1996-03 Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group in ANNALS OF HEMATOLOGY
  • 1994-05 In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity in ANNALS OF HEMATOLOGY
  • 1993-05 Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics in ANNALS OF HEMATOLOGY
  • 1992 Mitoxantrone: Pharmacokinetic and Pharmacodynamic Studies in Patients with Leukemia in ACUTE LEUKEMIAS
  • 1991-07 1-β-D-arabinofuranosylcytosine (Ara-C) enhances mitochondrial activities in human leukaemic cells in BRITISH JOURNAL OF CANCER
  • 1986-07 The effect of cytosine arabinoside upon mitochondrial staining kinetics in human hematopoietic cells in HISTOCHEMISTRY AND CELL BIOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.415967.8", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413172.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.24381.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411544.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.16872.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411841.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4488.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.239578.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417068.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413780.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420036.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.270240.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413591.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.429705.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6530.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411394.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411374.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415756.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.46699.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418936.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417886.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10417.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240684.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5963.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4714.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412180.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.11318.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9122.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.449710.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.459950.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5590.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.170205.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414867.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5596.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.51462.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.443984.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10419.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412688.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411327.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.18887.3e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413009.f", 
            "type": "Organization"
          }
        ], 
        "familyName": "Muus", 
        "givenName": "Petra", 
        "id": "sg:person.01054761151.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054761151.73"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-09-02T16:35", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/person/person_816.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01054761151.73'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01054761151.73'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01054761151.73'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01054761151.73'


     

    This table displays all metadata directly associated to this object as RDF triples.

    100 TRIPLES      10 PREDICATES      53 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01054761151.73 schema:affiliation Nb82219d039134656bb2d1e13b974cd41
    2 grid-institutes:grid.10417.33
    3 grid-institutes:grid.10419.3d
    4 grid-institutes:grid.11318.3a
    5 grid-institutes:grid.16872.3a
    6 grid-institutes:grid.170205.1
    7 grid-institutes:grid.18887.3e
    8 grid-institutes:grid.239578.2
    9 grid-institutes:grid.240145.6
    10 grid-institutes:grid.240684.c
    11 grid-institutes:grid.24381.3c
    12 grid-institutes:grid.270240.3
    13 grid-institutes:grid.410569.f
    14 grid-institutes:grid.411327.2
    15 grid-institutes:grid.411374.4
    16 grid-institutes:grid.411394.a
    17 grid-institutes:grid.411544.1
    18 grid-institutes:grid.411841.9
    19 grid-institutes:grid.412180.e
    20 grid-institutes:grid.412688.1
    21 grid-institutes:grid.413009.f
    22 grid-institutes:grid.413172.2
    23 grid-institutes:grid.413591.b
    24 grid-institutes:grid.413780.9
    25 grid-institutes:grid.414867.8
    26 grid-institutes:grid.415756.4
    27 grid-institutes:grid.417068.c
    28 grid-institutes:grid.417886.4
    29 grid-institutes:grid.418936.1
    30 grid-institutes:grid.420036.3
    31 grid-institutes:grid.429705.d
    32 grid-institutes:grid.443984.6
    33 grid-institutes:grid.4488.0
    34 grid-institutes:grid.449710.f
    35 grid-institutes:grid.459950.4
    36 grid-institutes:grid.46699.34
    37 grid-institutes:grid.4714.6
    38 grid-institutes:grid.51462.34
    39 grid-institutes:grid.5590.9
    40 grid-institutes:grid.5596.f
    41 grid-institutes:grid.5963.9
    42 grid-institutes:grid.6530.0
    43 grid-institutes:grid.9122.8
    44 schema:familyName Muus
    45 schema:givenName Petra
    46 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054761151.73
    47 schema:sdDatePublished 2022-09-02T16:35
    48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    49 schema:sdPublisher N6769de21e9f24accaa2a63a6acaf0d5c
    50 sgo:license sg:explorer/license/
    51 sgo:sdDataset persons
    52 rdf:type schema:Person
    53 N6769de21e9f24accaa2a63a6acaf0d5c schema:name Springer Nature - SN SciGraph project
    54 rdf:type schema:Organization
    55 Nb82219d039134656bb2d1e13b974cd41 schema:affiliation grid-institutes:grid.415967.8
    56 sgo:isCurrent true
    57 rdf:type schema:OrganizationRole
    58 grid-institutes:grid.10417.33 schema:Organization
    59 grid-institutes:grid.10419.3d schema:Organization
    60 grid-institutes:grid.11318.3a schema:Organization
    61 grid-institutes:grid.16872.3a schema:Organization
    62 grid-institutes:grid.170205.1 schema:Organization
    63 grid-institutes:grid.18887.3e schema:Organization
    64 grid-institutes:grid.239578.2 schema:Organization
    65 grid-institutes:grid.240145.6 schema:Organization
    66 grid-institutes:grid.240684.c schema:Organization
    67 grid-institutes:grid.24381.3c schema:Organization
    68 grid-institutes:grid.270240.3 schema:Organization
    69 grid-institutes:grid.410569.f schema:Organization
    70 grid-institutes:grid.411327.2 schema:Organization
    71 grid-institutes:grid.411374.4 schema:Organization
    72 grid-institutes:grid.411394.a schema:Organization
    73 grid-institutes:grid.411544.1 schema:Organization
    74 grid-institutes:grid.411841.9 schema:Organization
    75 grid-institutes:grid.412180.e schema:Organization
    76 grid-institutes:grid.412688.1 schema:Organization
    77 grid-institutes:grid.413009.f schema:Organization
    78 grid-institutes:grid.413172.2 schema:Organization
    79 grid-institutes:grid.413591.b schema:Organization
    80 grid-institutes:grid.413780.9 schema:Organization
    81 grid-institutes:grid.414867.8 schema:Organization
    82 grid-institutes:grid.415756.4 schema:Organization
    83 grid-institutes:grid.415967.8 schema:Organization
    84 grid-institutes:grid.417068.c schema:Organization
    85 grid-institutes:grid.417886.4 schema:Organization
    86 grid-institutes:grid.418936.1 schema:Organization
    87 grid-institutes:grid.420036.3 schema:Organization
    88 grid-institutes:grid.429705.d schema:Organization
    89 grid-institutes:grid.443984.6 schema:Organization
    90 grid-institutes:grid.4488.0 schema:Organization
    91 grid-institutes:grid.449710.f schema:Organization
    92 grid-institutes:grid.459950.4 schema:Organization
    93 grid-institutes:grid.46699.34 schema:Organization
    94 grid-institutes:grid.4714.6 schema:Organization
    95 grid-institutes:grid.51462.34 schema:Organization
    96 grid-institutes:grid.5590.9 schema:Organization
    97 grid-institutes:grid.5596.f schema:Organization
    98 grid-institutes:grid.5963.9 schema:Organization
    99 grid-institutes:grid.6530.0 schema:Organization
    100 grid-institutes:grid.9122.8 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...